Scancell Share Discussion Threads

[inanaco] 11/3/2018 13:05

Fragma ...

Left behind .. Left Wing ..... 1970 technology ... nationalise

[the real lozan] 11/3/2018 13:03

Could ANY of the SCAMMER LIARS show ANY post of mine, in which I HAVE =
"URGED ANYONE to sell {sell, sell}"
.
NO - YOU CAN't

[fragma] 11/3/2018 12:48

Lozer, of course not, but how would it differ from you urging everyone to sell, sell, sell.

When even the Asstute claim to have been buying. You seem to have been left behind

[fragma] 11/3/2018 12:44

Red army, would you care to elaborate.

Maybe you could tell us why the worlds top clinicions, oncologists, research charities, Europes largest private bio company and other world leading companies have got it wrong, and you have got it right ?

As it has all been announced in the last couple of months, you could be forgiven for not understanding if you havnt read the last few RNS's.

[the real lozan] 11/3/2018 12:43

FragSCAMMER -
You wouldn't - by any chance- be 'urging' me [and others] to BUY,BUY,BUY
Would you ???

[inanaco] 11/3/2018 12:43

Fragma

he needs a "kick Start Loan " .... the old timer has done his capital ...

Our Man Loz followed Milymogg and Yoda

[chelsea35] 11/3/2018 12:32

red army................red army10 Mar '18 - 21:12 - 14467 of 14473
0 1 1
"""Does not sound that great to me or am I missing something.
Still work in progress."""

Welcome to ADVFN, you are not alone.

[fragma] 11/3/2018 12:24

And not surprising at all to see the Lozer wallowing in self pity and the usual delusion.

It,s not too late too get yourself some shares Lozan, you might make back the money you lost in the first place which put you into this state of despair.

[red army] 11/3/2018 09:16

Forgot to say thanks very much for the notes and information Timbo.

[torquayfan] 11/3/2018 00:10

TIMBO - thanks for all that and for this passage in particular. I seem to remember that the SCIB1 8mg double dose gave a MUCH improved response and there were questions at the time as to why there was no progression to 12 or 16 mg dose after 2,4,8 mg. There's the answer - I may have missed it before. I have always wondered if the Ichor was the drawback or the reason for 'slow' interest from Pharma in Immunobody.

Is there another LEAP forward on the way - Immunobody 2 ?

''Q: Are you still planning to use the Ichor Trigrid device for the SCIB2 study? (note: Scancell are contractually obliged to use Trigrid for SCIB1, but not for SCIB2) A: We are now looking at other technologies which could obviate the need for Trigrid and in particular nanovesicles. We have found that nanovesicles can improve drug delivery compared to Trigrid by a factor of 4 (I think RG said 4, others who were there may be able to confirm). The method does not require electrophoresis in order to get the drug into the cells, so there are no painful intra muscular injections and no electric shocks, instead the drug would probably be delivered by a simple (relatively painless) conventional method such as subcutaneous injection (or infusion for larger volumes) Comment: I have long believed that Scancell should do all they can to move away from Trigrid for delivery of the immunobody formulations. The device looks a bit like a ray gun from a 1950s Sci-Fi movie (see link below) and the procedure is allegedly painful (Gruesome). However despite these drawbacks, Scancell would still have to pay for a licence (or pay royalties) in order to use Trigrid commercially. Another associated problem with using Trigrid for Immunobody is that there are limitations on how much drug can be administered due to volume constraints and viscosity concerns, the maximum amount of SCIB1 that can administered via Trigrid is 8mg (4mg in each arm), whereas the optimal dose (based on animal studies) would be 20mg which is just not feasible (see link to notes from Proactive meeting Nov 2016 below). Similar dose limitations may also apply to SCIB2. Should the work with nanovesicles continue to look promising and nanovesicles were to replace Trigrid for SCIB2, then that would be a significant step forward for the immunobody platform.''

Thanks again . . .

[inanaco] 10/3/2018 23:29

Thanks Timbo

[10acious] 10/3/2018 22:53

timbo,Thank you for your feedback, some interesting questions and responses!Very much appreciated as always.10

[red army] 10/3/2018 21:12

Does not sound that great to me or am I missing something.
Still work in progress.

[rhatton] 10/3/2018 21:11

Thanks for your update Timbo! Much appreciated.
Could I ask you two questions,
1. What’s your option of the SCIB1 combo trial patient numbers being reduced to 19 from the original 80 odd I think?
2. Is it too late in the day to look at another delivery method for SCIB1 combo?

Many thanks

[timbo003] 10/3/2018 20:58

Herewith a few notes (written as a Q&A) summarising the discussion with RG and other shareholders following Thursday’s Proactive investor meeting (also see relevant links at the end of this report). The notes are not a verbatim account; they are intended to provide a balanced account of what was discussed.

There were just three companies presenting at the meeting. Scancell were the only company that traded on a public market, the other two were unquoted and therefore of less interest to many of the attendees, therefore it was not surprising that RG had a lot of investors wanting to quiz him after the meeting. I opted to wait until around half of the attendees had departed before I joined in.



Q: Are you still planning to use the Ichor Trigrid device for the SCIB2 study? (note: Scancell are contractually obliged to use Trigrid for SCIB1, but not for SCIB2)

A: We are now looking at other technologies which could obviate the need for Trigrid and in particular nanovesicles. We have found that nanovesicles can improve drug delivery compared to Trigrid by a factor of 4 (I think RG said 4, others who were there may be able to confirm). The method does not require electrophoresis in order to get the drug into the cells, so there are no painful intra muscular injections and no electric shocks, instead the drug would probably be delivered by a simple (relatively painless) conventional method such as subcutaneous injection (or infusion for larger volumes)

Comment: I have long believed that Scancell should do all they can to move away from Trigrid for delivery of the immunobody formulations. The device looks a bit like a ray gun from a 1950s Sci-Fi movie (see link below) and the procedure is allegedly painful (Gruesome). However despite these drawbacks, Scancell would still have to pay for a licence (or pay royalties) in order to use Trigrid commercially.
Another associated problem with using Trigrid for Immunobody is that there are limitations on how much drug can be administered due to volume constraints and viscosity concerns, the maximum amount of SCIB1 that can administered via Trigrid is 8mg (4mg in each arm), whereas the optimal dose (based on animal studies) would be 20mg which is just not feasible (see link to notes from Proactive meeting Nov 2016 below). Similar dose limitations may also apply to SCIB2.
Should the work with nanovesicles continue to look promising and nanovesicles were to replace Trigrid for SCIB2, then that would be a significant step forward for the immunobody platform.
A google search on Nanovesicles for drug delivery, suggests it is a fairly active area. However, I am not totally clear on how Nanovesicles differ from some of the other Nano drug delivery systems such as exosomes. One recent paper published in Nature (see link below) seems to make a distinction between Nanovesicles (CDNs) and Exosomes, so I will go along with that one for now.


Q: The new swimmer plot from the SCIB1 trial looks impressive (see link below) and it’s an excellent way to summarise the SCIB1 data. Do we know anything about how the individual patients are doing now the study is complete now and can we assign a name to each swimmer? In addition do we know which one of the swimmers is Tom, the SCIB1 patient who appeared in a couple of videos a few years ago talking about his treatment? (See links to videos below)

A: We don’t know the identity of any of the patients on the Swimmer plot and we don’t know their current status.

Comment: Taking the info from the videos and using appropriate search terms you should be able to obtain an answer within a couple of minutes. Note also that in the first video the patient describes the drug dosing stage using the Ichor device as Gruesome


Q: Who sits on the judging panel for the Grand Challenge?

A: We don’t know who does the judging, what is important is that being selected for the short list has raised Scancell’s profile in the world of Oncology, furthermore it has enabled Scancell to establish contacts and build better relationships with many more KOLs and decision makers than before.


Q: How much headroom do you have for another EIS/VCT fund raise, should this prove necessary?

A: We could raise another £2M under the EIS/VCT scheme. That would take us up to the £20 lifetime limit.



Q: Is there any early R&D going on which we haven’t heard about this evening?

A: Lindy and team have been conducting early work which could lead to a new therapeutic platform similar to Moditope in that it would utilise a post translational modification (PTM), but unlike Moditope it would not involve the arginine to citrulline PTM (see wiki entry for PTM below).

Comment: This topic came up towards the end of the evening and my brain was already in overload so I’m not sure that I have got the details right on this and I don’t know whether the intention is to target cancers, it could be some other indication.


Slide set from Thursday’s meeting:
Sound recording from Thursday’s meeting:
Notes from Scancell AGM (Oct 2017):
Notes from Proactive meeting (July 2017):
Notes from Proactive meeting (Jan 2017):
Notes from Proactive meeting (July 2016):
Ichor’s TriGrid device:
Interview with SCIB1 patient:
Expert panel discussion with SCIB1 patient:
Nature (2017):
SCIB1 Swimmer Plot:
Post Translational Modification (wiki):

[inanaco] 10/3/2018 14:00

But then i suppose only wealthy individuals benefit from that, they can afford to hold

they don't need the fire wood


which proves another point ... Loz did not get any allocated shares in the 22p OO

.... yet again proof he has no money or shares

Thank you loz.

game in play trip them up ....

[inanaco] 10/3/2018 13:52

EIS you have to hold them 3 years before the tax exemption takes effect ...

[inanaco] 10/3/2018 13:16

Terror must be happy ..
Mr W is happy
Panama7 is happy
Gazza for sure is happy


why is Loz and Tosh not happy ... read it all in the book .... "mist opportunity"

[inanaco] 10/3/2018 13:11

all my shares are now tax free lozan, through tactical play ...

all your shares are tax free as you don't have any ... what a bonus for you

[inanaco] 10/3/2018 12:37

Lozan ... writes a new book on the weather, and the dark side under Mist

its called the "Mist Opportunity"

Pity you have no shares by the way ...